Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway

Uluer, Elgin Türköz; Aydemir, Işıl; İnan, Sevinç; Özbilgin, Kemal; Vatansever, Hafize Seda

doi:10.1016/j.acthis.2011.11.010

Cited by 26 publications

(15 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…STAT2, forming heteromeric complexes with STAT1, was found in MCF7 cells, an ER+ human BC cell line [23]. In the current study, STAT2 was increased in BC tissues, similar with STAT1.…”

Section: Discussionsupporting

confidence: 70%

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Signal Transducer and Activators of Transcription (STAT) is a set of transcription factors, involved in diverse cellular functions. Evidences from cell lines, mouse models and human tissues implicate these transcription factors in the oncogenesis of breast cancer. However, the diverse expression patterns and prognostic values of 7 STATs remain to be elucidated. In the current study, we mined the transcriptional and survival data of STATs in patients with breast carcinoma (BC) through ONCOMINE, bc-GenExMiner, Kaplan-Meier Plotter and cBioPortal. It was found that STAT1/2 were up-regulated, whereas STAT3/4/5A/5B were down-regulated in BC patients compared with the normal tissues. The expressions of STAT5A/5B/6 were correlated with decreased levels of histological differentiation. In survival analyses through the Kaplan-Meier plotter database, high transcription levels of STAT2/4/5A/5B/6 were associated with better relapse-free survival (RFS) in all BC patients. Conversely, high STAT3 predicted shorter RFS in BC patients, suggesting that STAT3 is potential targets for precision therapy to BC patients. These data also provided STAT5A/5B/6 as new biomarker for BC prognosis.

show abstract

“…STAT2, forming heteromeric complexes with STAT1, was found in MCF7 cells, an ER+ human BC cell line [23]. In the current study, STAT2 was increased in BC tissues, similar with STAT1.…”

Section: Discussionsupporting

confidence: 70%

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

“…Another example of this type is the pro-apoptotic STAT2 and the alkylating agent uracil mustard. STAT2 has had prior reported association with DNA synthesis inhibitors (31); however genes that affect apoptosis might be expected to influence the response to multiple drug types. In addition, one can identify unstudied compounds that may target potentially pharmacologically useful genes, such as the epithelial-mesenchymal associated tight junction protein 3 (TJP3).…”

Section: Genetic Variant Versus Drug Visualizationmentioning

confidence: 99%

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60

Reinhold

Sunshine

Varma

et al. 2015

Clinical Cancer Research

106

View full text Add to dashboard Cite

The NCI-60 cancer cell line panel provides a premier model for data integration and systems pharmacology being the largest publicly available database of anticancer drug activity,, genomic, molecular, and phenotypic data. It comprises gene expression (25,722 transcripts), microRNAs (360 miRNAs), whole genome DNA copy number (23,413 genes), whole exome sequencing (variants for 16,568 genes), protein levels (94 genes), and cytotoxic activity (20,861 compounds). Included are 158 Food and Drug Administration (FDA)-approved drugs and 79 that are in clinical trials. To improve data accessibility to bioinformaticists and non-bioinformaticists alike, we have developed the CellMiner web-based tools. Here we describe the newest CellMiner version, including integration of novel databases and tools associated with whole exome sequencing and protein expression, and review the tools. Included are i) “Cell line signature” for DNA, RNA, protein and drugs, ii) “Cross correlations” for up to 150 input genes, microRNAs, and compounds in a single query, iii) “Pattern comparison” to identify connections among drugs, gene expression, genomic variants, microRNA and protein expressions, iv) “Genetic variation versus drug visualization” to identify potential new drug:gene DNA variant relationships, and v) “Genetic variant summation”, designed to provide a synopsis of mutational burden on any pathway or gene group for up to 150 genes. Together, these tools allow users to flexibly query the NCI-60 data for potential relationships between genomic, molecular and pharmacological parameters in a manner specific to the user’s area of expertise. Examples for both gain- (RAS) and loss- (PTEN) of-function alterations are provided.

show abstract

“…It has also been demonstrated that in cellular models, STAT activation can result in increased cell survival and even escape from differentiation24. Fortunately, despite the crucial role which STAT activation plays in tumor development and progression, 5-FU could significantly decrease STAT activation in cancer cells and indicated a better effect than gemcitabine according to a previous breast cancer research25. 5-FU is an antimetabolite drug and functions its anti-tumor capability through blocking several essential biosynthetic processes, or incorporating itself into macromolecules as RNA or DNA to inhibit their normal biological function26.…”

Section: Discussionmentioning

confidence: 99%

Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer

Cao

Zhang

Liu

et al. 2016

Sci Rep

View full text Add to dashboard Cite

The interaction of glycoprotein 130 (gp130) with the cytokines of Interleukin-6 (IL-6) family has proved to play a crucial part in several cancers. Our current study is designed to discover the clinical prognostic significance of gp130 in non-metastatic gastric cancer. We examined intratumoral gp130 expression in retrospectively enrolled 370 gastric cancer patients who underwent radical gastrectomy with standard D2 lymphadenectomy at Zhongshan Hospital of Fudan University during 2007 and 2008 by immunohistochemical staining. The expression of gp130 was significantly correlated with T classification, N classification and TNM stage (P = 0.003, P < 0.001 and P < 0.001, respectively; T, N, TNM refers to Tumor Invasion, Regional lymph node metastasis and Tumor Node Metastasis, respectively). Elevated intratumoral gp130 expression implied unfavourable overall survival (OS) (P < 0.001) and disease-free survival (DFS) (P < 0.001), respectively. Furthermore, among TNM II and III gp130-high patients, those who were treated with 5-fluorouracil (5-FU) based adjuvant chemotherapy had better OS (P < 0.001). The generated nomogram performed well in predicting the 3- and 5-year OS of gastric cancer patients. The incorporation of gp130 into contemporary TNM staging system would be of great significance to improve the current individual risk stratification. These findings contribute to better clinical management for those patients who would benefit from adjuvant chemotherapy.

show abstract

Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway

Cited by 26 publications

References 45 publications

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma

Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60

Glycoprotein 130 is associated with adverse postoperative clinical outcomes of patients with late-stage non-metastatic gastric cancer

Contact Info

Product

Resources

About